Skip to main content

Table 2 Univariate and multivariate analysis for PFS and OS. Cox’s regression model taking into account the IHC data or NLR at diagnosis

From: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer

Variable

Univariate (OS)

P value

Multivariate (OS)

P value

 NLR >5 vs NLR ≤5

2.39 (1.48–3.85)

0.0001**

1.99 (1.2–3.3)

0.007**

 RAS Mut vs WT

2.07 (1.28–3.34)

0.003 **

1.88 (1.16–3.06)

0.01*

 Multiple vs single metastases

1.34 (0.99–1.81)

0.056

1.30 (0.91–1.86)

0.13

 CD15/FUT4 high vs low/neg

1.95 (1.37–2.98)

0.001**

1.55 (1.06–2.89)

0.056

Variable

Univariate (PFS)

P value

Multivariate (PFS)

P value

 NLR >5 vs NLR ≤ 5

2.41 (1.37–4.22)

0.002**

2.47 (1.4–4.34)

0.05*

 Stage at diagnosis III and IV vs II

1.42 (1.05–1.91)

0.021*

1.3 (0.928–1.81)

0.127

 Histotype mucinous vs others

1.60 (1.0–2.57)

0.05*

1.43 (0.89–2.32)

0.136

 CD15/FUT4 high vs low/neg

3.37 (2.14–5.51)

0.0001**

2.92 (1.86–4.61)

0.001**

  1. Abbreviations: HR Hazard ratio, 95 % CI 95 % confidence interval, IHC Immunohistochemistry, NLR blood neutrophil-to-lymphocyte ratio
  2. *P ≤ .05; **P ≤ .01